These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8250120)

  • 1. [The use of tumor markers in the diagnosis and treatment monitoring of malignant tumors of the female genitalia].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar' BN; Khomenko LP
    Akush Ginekol (Mosk); 1993; (4):48-50. PubMed ID: 8250120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The determination of CA-125, CA-19-9 and CEA antigens in gynecologic patients for differential diagnosis and the assessment of the efficacy of surgical treatment and subsequent monitoring].
    Alekseeva ML; Andreeva EN; Novikov EA; Fanchenko ND; Seliverstov AA; Bobkova MV; Margiani FR
    Akush Ginekol (Mosk); 1995; (5):25-8. PubMed ID: 8579200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA 72-4 serum marker--a new tool in the management of carcinoma patients.
    Guadagni F; Roselli M; Cosimelli M; Ferroni P; Spila A; Cavaliere F; Casaldi V; Wappner G; Abbolito MR; Greiner JW
    Cancer Invest; 1995; 13(2):227-38. PubMed ID: 7874576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor markers in the diagnosis and prognosis of breast cancer].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
    Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of serum CA 19-9 and CEA levels in a population at high risk for colorectal cancer.
    Goldberg EM; Simunovic LM; Drake SL; Mueller WF; Verrill HL
    Hybridoma; 1989 Oct; 8(5):569-75. PubMed ID: 2807313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment levels of CEA, CA 19-9, CA 50 and CA 72-4 in sera of patients with squamous cell carcinoma of the oesophagus.
    Rakic S; Kalezic V; Grujic-Adanja G; Jagodic M
    Eur J Cancer Prev; 1993 Jul; 2(4):361. PubMed ID: 8358290
    [No Abstract]   [Full Text] [Related]  

  • 8. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
    Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
    Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas.
    Yedema CA; Kenemans P; Wobbes T; Thomas CM; Bon GG; Mulder C; Voorhorst FJ; Verstraeten AA; van Kamp GJ; Hilgers J
    Tumour Biol; 1992; 13(1-2):18-26. PubMed ID: 1589694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peri- and postoperative changes in serum levels of four tumor markers and three acute phase reactants in benign and malignant gynecological diseases.
    Avall-Lundqvist E; Sjövall K; Hansson LO; Eneroth P
    Arch Gynecol Obstet; 1992; 251(2):69-78. PubMed ID: 1374604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of seven tumor markers (CA 50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma.
    Wobbes T; Thomas CM; Segers MF; Nagengast FM
    Cancer; 1992 Apr; 69(8):2036-41. PubMed ID: 1544112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum values of CA72.4 in patients with gastrointestinal system tumors comparison with CEA and CA 19.9.
    Yasasever V; Sengün Z; Saydan N; Onat H; Dalay N
    Eur J Gynaecol Oncol; 1992; 13(5):403-8. PubMed ID: 1486919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
    Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
    Eur J Cancer; 1995 Sep; 31A(10):1615-21. PubMed ID: 7488411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
    Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
    Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of the tumor markers CA 125, Ca 19-9, CA 15-3 and CEA in endometriosis].
    Cirkel U; Ochs H; Latussek B; Schneider HP
    Geburtshilfe Frauenheilkd; 1991 Aug; 51(8):626-31. PubMed ID: 1936874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA 15-3 as a tumor marker in gynecological malignancies.
    Scambia G; Benedetti Panici P; Baiocchi G; Perrone L; Greggi S; Mancuso S
    Gynecol Oncol; 1988 Jun; 30(2):265-73. PubMed ID: 3163666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The diagnostic value of the tumor markers CEA, "Ca 19-9", "Ca 125", "Ca15-3" and "SCC" for the detection of recurrent tumors in patients with tumors of the head and neck].
    Zöller J; Fiehn W; Mende U; Hotz G
    Dtsch Z Mund Kiefer Gesichtschir; 1990; 14(4):254-9. PubMed ID: 2134649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K].
    Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C
    Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A system for tumor heterogeneity evaluation and diagnosis based on tumor markers measured routinely in the laboratory.
    Hui L; Rixv L; Xiuying Z
    Clin Biochem; 2015 Dec; 48(18):1241-5. PubMed ID: 26216289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence of CA 125 and CA 19-9 tumor-associated antigens in sera of patients with gynecologic, trophoblastic, and colorectal tumors.
    Göcze PM; Szabó DG; Than GN; Csaba IF; Krommer KF
    Gynecol Obstet Invest; 1988; 25(4):268-72. PubMed ID: 2841208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.